Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?

被引:55
作者
Marques, Thyciara Fontenele [1 ]
Vasconcelos, Renata [1 ]
Diniz, Erik [1 ]
Rego, Daniela [1 ]
Griz, Luiz [1 ]
Bandeira, Francisco [1 ]
机构
[1] Univ Pernambuco UPE, Sch Med, Brazilian Minist Hlth MS SUS, Div Endocrinol & Diabet,Hosp Agamenon Magalhaes, Recife, PE, Brazil
关键词
Normocalcemic hyperparathyroidism; osteoporosis; fractures; kidney stones; ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; TOTAL CALCIUM; DISEASE;
D O I
10.1590/S0004-27302011000500003
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective: To describe the characteristics of normocalcemic primary hyperparathyroidism (NPHPT) in patients seen for osteoporosis evaluation. Patients and methods: We examined the records of 156 women who came to the hospital to be screened for osteoporosis. Measurements of total calcium, PTH, 25-hydroxy vitamin D, and beta-C-telopeptide were recorded. Bone mineral density and T-scores were evaluated by densitometry of the lumbar spine, femoral neck and distal one-third of the radius. The latter was only measured in patients with primary hyperparathyroidism. Nephrolithiasis and bone fractures were documented by a review of the medical records. Res it We identified 14 patients with NPHPT, accounting for 8.9% of the population studied. In the medical records, the occurrence of kidney stones was reported in 28.6% of the patients with NPHPT, in contrast with only 0.7% of the noncarriers. Regarding the presence of general fractures, 21.4% of the patients with NPHPT were affected versus 16.2% of noncarriers. Conclusion: Data from our study suggest that NPHPT has a diverse phenotypic presentation, implying that this may not be an "indolent" disease. Arq Bras Endocrinol Metab. 2011;55(5):314-7
引用
收藏
页码:314 / 317
页数:4
相关论文
共 14 条
[1]
Bilezikian JP, 2002, J BONE MINER RES, V17, pN57
[2]
FORSTER J, 1988, SURGERY, V104, P1137
[3]
Glendenning P, 1998, AUST NZ J MED, V28, P173
[4]
Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype [J].
Lowe, H. ;
McMahon, D. J. ;
Rubin, M. R. ;
Bilezikian, J. P. ;
Silverberg, S. J. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08) :3001-3005
[5]
Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women [J].
Lundgren, E ;
Rastad, J ;
Thurfjell, E ;
Akerstrom, G ;
Ljunghall, S .
SURGERY, 1997, 121 (03) :287-294
[6]
Normocalcemic primary hyperparathyroidism: Evidence for a generalized target-tissue resistance to parathyroid hormone [J].
Maruani, G ;
Hertig, A ;
Paillard, M ;
Houillier, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10) :4641-4648
[7]
MULDOWNEY FP, 1976, Q J MED, V45, P75
[8]
PARFITT A M, 1991, Journal of Bone and Mineral Research, V6, pS97
[9]
Parfitt AM, 1991, J BONE MINER RES S2, V6
[10]
LACK OF BIOCHEMICAL PROGRESSION OR CONTINUATION OF ACCELERATED BONE LOSS IN MILD ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM - EVIDENCE FOR BIPHASIC DISEASE COURSE [J].
RAO, DS ;
WILSON, RJ ;
KLEEREKOPER, M ;
PARFITT, AM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (06) :1294-1298